BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15244384)

  • 1. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Schroeder G; Tefferi A
    Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
    Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
    Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
    J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
    Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
    Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
    Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
    Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide treatment in myelofibrosis with myeloid metaplasia.
    Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A
    Br J Haematol; 2002 May; 117(2):288-96. PubMed ID: 11972510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M
    Br J Haematol; 2001 Jul; 114(1):78-83. PubMed ID: 11472348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
    Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
    Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
    Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
    Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
    Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
    Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
    Berrebi A; Feldberg E; Spivak I; Shvidel L
    Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Merup M; Kutti J; Birgergård G; Mauritzson N; Björkholm M; Markevärn B; Maim C; Westin J; Palmblad J;
    Med Oncol; 2002; 19(2):79-86. PubMed ID: 12180484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
    Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
    J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
    Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
    J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
    Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
    Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
    Faoro LN; Tefferi A; Mesa RA
    Eur J Haematol; 2005 Feb; 74(2):117-20. PubMed ID: 15654901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide in agnogenic and secondary myelofibrosis.
    Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
    Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.